Optimizing Postneoadjuvant Treatment in Patients With Early Breast Cancer Achieving Pathologic Complete Response

J Clin Oncol. 2024 Apr 3:JCO2301935. doi: 10.1200/JCO.23.01935. Online ahead of print.

Carmine Valenza^{1

2}, Dario Trapani^{1

2}, Sibylle Loibl³, Stephen K L Chia⁴, Harold J Burstein^{5

6

7}, Giuseppe Curigliano^{1

2}

¹ Division of New Drugs and Early Drug Development for Innovative Therapies, European Institute of Oncology, IRCCS, Milan, Italy.
² Department of Oncology and Hemato-Oncology, University of Milan, Milan, Italy.
³ Center for Hematology and Oncology Bethanien, Frankfurt, Germany.
⁴ BC Cancer Agency, Vancouver, BC, Canada.
⁵ Medical Oncology, Dana-Farber Cancer Institute, Boston, MA.
⁶ Breast Oncology Program, Dana-Farber Brigham Cancer Center, Boston, MA.
⁷ Harvard Medical School, Boston, MA.

Abstract

pCR should be integrated with other prognostic factors to optimize postneoadjuvant treatments in BC.